Product Pipeline

Our innovative approach has resulted in multiple drug candidates that offer improved ways to target a broad range of disease areas. Our lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. We are also assessing a number of earlier-stage pipeline candidates.

Lead Indications
Preclinical
Phase 1
Phase 2
Phase 3
plus-minus
CTP-543 Deuterated ruxolitinib
Alopecia Areata
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 

An investigational JAK inhibitor designed to target the immunological basis of alopecia areata. CTP-543 is an oral inhibitor of Janus kinases JAK1 and JAK2. Learn more >


Warning: Illegal string offset 'avp_786_text' in /home/customer/www/concertpharma.com/public_html/wp-content/themes/Orchestra/page-pipeline.php on line 148

Strategic Collaborations

Concert’s platform has driven product development programs and resulted in novel drugs that are being developed under strategic collaborations.

Back to Top